Sanofi
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sanofi is a global biopharmaceutical leader involved in the exploration, development, manufacturing, and commercialization of diverse therapeutic solutions across various international markets. The company operates primarily through its focused segments of Pharmaceuticals and Vaccines, undergoing a strategic evolution to center on innovative biopharmaceutical advancements. Within its Pharmaceutical division, Sanofi delivers specialized care products, including advanced treatments for immunology, such as human monoclonal antibodies, and therapies addressing multiple sclerosis, other neurological conditions, inflammatory diseases, rare disorders, oncology, and specific rare blood conditions. The Vaccines segment remains a cornerstone, providing immunizations for diseases like poliomyelitis, pertussis, influenza, meningitis, and other booster and travel-related vaccines, serving populations globally. In a significant strategic realignment, Sanofi has moved to divest a controlling stake in its Consumer Healthcare unit, Opella, to intensify its focus on high-growth biopharma areas and enhance its research and development capabilities. The company generates revenue predominantly through the sale of its innovative pharmaceutical products and vaccines, complemented by income from licensing agreements, collaborations, and strategic partnerships. Its target market includes a broad spectrum of healthcare providers, such as hospitals, clinics, and pharmacies, alongside patients requiring specialized medical care. Recent initiatives highlight Sanofi's commitment to scientific breakthroughs, with substantial investments in research and development, particularly in immunology and oncology. Key developments include the acquisition of Inhibrx in early 2024 to bolster its rare disease pipeline, a collaboration with Orano Med in late 2024 for next-generation radioligand therapies in oncology, and the buyout of Vigil Neuroscience in May 2025. Furthermore, Sanofi Ventures committed additional capital in September 2025 to foster early-stage biotech and digital health innovations. Its robust pipeline currently features 93 clinical-stage projects, with 36 in Phase 3 or under regulatory review as of October 2025. The company also achieved a positive CHMP recommendation in November 2025 for Teizeild (teplizumab) for stage 2 type 1 diabetes in the European Union. Sanofi was established in 1973 and maintains its headquarters in Paris, France.
Company News
Enable Injections Announces Approval in Japan for CirCLIQ® Injector based on enFuse® On-Body Delivery System
Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
EU Accepts Sanofi's Concessions to Settle Antitrust Probe Over Vaccine Marketing
Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)
Press Release : Availability of the aide-mémoire for Q3 2026 results
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?